At the news
? BULLISHIMPACT 8/10 8-K filed Apr 28, 2026 at 06:36 ET
Omnicell reported strong Q1 2026 results with total revenue of $310M (+15% YoY), GAAP EPS of $0.25 (vs -$0.15), and non-GAAP EPS of $0.55 (vs $0.26). The company raised full-year 2026 non-GAAP EBITDA and EPS guidance, signaling accelerating profitability and demand for its medication management solutions.
- Q1 2026 total revenue $310M, up 15% YoY from $270M
- GAAP net income $11M ($0.25/diluted share) vs loss of $7M (-$0.15)
- Non-GAAP net income $25M ($0.55/diluted share) vs $12M ($0.26)
- Operating cash flow $55M, up from $26M YoY
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access